BNKL
Bionik Laboratories Corp.Company Information
- Company Name
- Bionik Laboratories Corp.
- CIK
- CIK0001508381
- Category
- Non-accelerated filer<br>Smaller reporting company
- Ticker: Exchange
- BNKL: OTC
- Fiscal Year End
- March 31
- Owner Organization
- Not Available
- SIC
- 3842
- SIC Description
- Orthopedic, Prosthetic & Surgical Appliances & Supplies
- Ticker
- BNKL
SEC filing data through
Insider Sentiment
- Last purchase
- 2023-06-09
- Last sale
- —
- Shares purchased (TTM)
- 1,011,110
- Shares sold (TTM)
- 0
Institutional Sentiment
- As of
- —
- Institutional shares owned
- —
- Shares outstanding
- —
- Ownership
- —
Earnings Market Reaction
- Filing date
- 2023-06-21
- Price on filing date
- —
- 1-month reaction
- -18.03%
- 3-month reaction
- -57.38%
Balance Sheet
Values in millions ($)| Line item | 2023-03-31 | 2022-12-31 | 2022-09-30 | 2022-06-30 | 2022-03-31 | 2021-12-31 | 2021-09-30 | 2021-06-30 | 2021-03-31 | 2020-12-31 | 2020-09-30 | 2020-06-30 | 2020-03-31 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets Current | |||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 0 | 1 | 0 | 1 | 2 | 3 | 5 | 1 | 1 | 1 | 1 | 2 | 2 | ||||||
| Accounts Receivable Net Current | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | ||||||
| Prepaid Expense And Other Assets Current | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | ||||||
| Inventory Net | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
| Assets Current | 3 | 3 | 3 | 4 | 5 | 6 | 7 | 3 | 3 | 4 | 5 | 6 | 6 | ||||||
| Due From Related Parties Current | - | - | - | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 | ||||||
| Property Plant And Equipment Net | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Other Assets Noncurrent | 0 | 0 | 0 | - | 0 | - | - | - | - | - | - | - | - | ||||||
| Intangible Assets Net Excluding Goodwill | - | - | - | - | 0 | - | 1 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
| Operating Lease Right Of Use Asset | 0 | 0 | 0 | - | 0 | - | - | - | - | - | - | - | - | ||||||
| Finite Lived Intangible Assets Net | 0 | 0 | 0 | - | 0 | - | - | - | - | - | - | - | - | ||||||
| Goodwill | 0 | 0 | 0 | - | 0 | 0 | 4 | 4 | 4 | 4 | 11 | 11 | 11 | ||||||
| Assets | 3 | 4 | 4 | 4 | 5 | 6 | 12 | 9 | 9 | 9 | 17 | 19 | 19 | ||||||
Liabilities Current | |||||||||||||||||||
| Accounts Payable Current | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 1 | 0 | 1 | ||||||
| Convertible Notes Payable Current | - | - | - | - | 0 | 9 | 8 | - | 2 | 4 | 4 | 3 | - | ||||||
| Accrued Liabilities Current | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | ||||||
| Short Term Borrowings | - | - | - | - | - | - | - | 2 | 2 | - | - | - | 2 | ||||||
| Operating Lease Liability Current | 0 | 0 | 0 | - | 0 | - | - | - | - | - | - | - | - | ||||||
| Contract With Customer Liability Current | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | ||||||
| Liabilities Current | 2 | 2 | 2 | 2 | 1 | 10 | 10 | 4 | 4 | 7 | 7 | 7 | 5 | ||||||
| Long Term Debt Noncurrent | - | - | - | - | 0 | 0 | 0 | 2 | 1 | - | - | - | 0 | ||||||
| Operating Lease Liability Noncurrent | 0 | 0 | 0 | - | 0 | - | - | - | - | - | - | - | - | ||||||
| Contract With Customer Liability Noncurrent | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | - | 0 | ||||||
| Convertible Long Term Notes Payable | 2 | 2 | 1 | 1 | 0 | - | - | - | - | - | - | - | - | ||||||
| Liabilities | 5 | 4 | 3 | 2 | 2 | 10 | 10 | 6 | 6 | 8 | - | - | 5 | ||||||
Stockholders Equity | |||||||||||||||||||
| Preferred Stock Value | 0 | - | - | - | 0 | - | - | - | 0 | - | 0 | 0 | - | ||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Additional Paid In Capital | 99 | 98 | 98 | 98 | 98 | 89 | 89 | 88 | 88 | 85 | 85 | 85 | 85 | ||||||
| Retained Earnings Accumulated Deficit | -100 | -99 | -98 | -97 | -95 | -94 | -87 | -85 | -85 | -84 | -75 | -73 | -71 | ||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Stockholders Equity | -2 | -1 | 1 | 2 | 3 | -4 | 2 | 3 | 3 | 1 | 10 | 12 | 13 | ||||||
| Liabilities And Stockholders Equity | 3 | 4 | 4 | 4 | 5 | 6 | 12 | 9 | 9 | 9 | 17 | 19 | 19 | ||||||
| Special Voting Preferred Stock | 0 | 0 | 0 | 0 | 0 | - | - | - | 0 | - | - | - | - | ||||||
| Allowance For Doubtful Accounts Receivable Current | - | - | - | - | - | - | - | - | 0 | - | - | 0 | 0 | ||||||
| Preferred Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Preferred Stock Shares Authorized | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 10 | 10 | 10 | ||||||
| Preferred Stock Shares Issued | 0 | - | - | - | 0 | - | - | - | 0 | 0 | - | - | 0 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock Shares Authorized | 13 | 13 | 13 | 13 | 13 | 13 | 13 | 13 | 13 | 13 | 500 | 500 | 500 | ||||||
| Common Stock Shares Issued | 7 | 7 | 7 | 7 | 7 | 6 | 6 | 6 | 7 | 5 | 5 | 5 | 5 | ||||||
| Shares Outstanding | - | - | - | - | - | - | - | - | - | - | 5 | 5 | 5 | ||||||
Select a line item above to chart it.
Recent filings
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialBionik Laboratories Corp. (BNKL) — SEC Financial Statements & Analysis
Bionik Laboratories Corp. (BNKL) is a orthopedic, prosthetic & surgical appliances & supplies company, incorporated in DE. Bionik Laboratories Corp. trades on OTC as: BNKL. Bionik Laboratories Corp. (BNKL)'s most recent SEC filing is a Form 10-K for the period ended 2023-03-31, filed with the SEC on 2023-06-21. Based on its latest SEC filing (Form 10-Q, period ending 2023-03-31), Bionik Laboratories Corp. carries a market cap of $2.76M, a P/E ratio of -0.56x, a P/B ratio of -1.68x, a P/S ratio of 1.53x, an enterprise value of $4.49M, and an EV/EBITDA multiple of -0.94x. On profitability, it posts a gross margin of 54.83%, an operating margin of -267.29%, a net margin of -273.99%, a Return on Equity (ROE) of -768.84%, a Return on Assets (ROA) of -123.07%, and a Return on Invested Capital (ROIC) of -889.21%. Per share, it reports EPS of $-0.72, diluted EPS of $-0.72, free cash flow per share of $-0.49, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of 41.73% year-over-year, net income growth of -52.48% year-over-year, and EPS growth of -59.77% year-over-year. On the balance sheet, it maintains a current ratio of 1.20x, a quick ratio of 0.38x, working capital of $468.38K, a debt-to-equity ratio of -3.05x, a debt ratio of 1.49, an interest coverage ratio of -45.03x, free cash flow of $-3.40M (TTM), and net debt of $1.73M. Figures sourced from SEC EDGAR.
- Market Cap
- $2.76M
- P/E TTM
- -0.56x
- EPS TTM
- $-0.72
- P/B TTM
- -1.68x
- ROE TTM
- -768.84%
- ROA TTM
- -123.07%
- Debt To Equity
- -3.05x
- Free Cash Flow TTM
- $-3.40M
- Net Revenue TTM Growth 1Y
- 41.73%
Data as of 2023-03-31 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Bionik Laboratories Corp. in?
Bionik Laboratories Corp. (BNKL) operates in the Orthopedic, Prosthetic & Surgical Appliances & Supplies industry.
What exchange does BNKL trade on?
Bionik Laboratories Corp. (BNKL) trades on the OTC.
Where is Bionik Laboratories Corp. incorporated?
Bionik Laboratories Corp. is incorporated in DE.
When was Bionik Laboratories Corp. (BNKL)'s most recent SEC filing?
Bionik Laboratories Corp. (BNKL)'s most recent SEC filing is a Form 10-K for the period ended 2023-03-31, filed with the SEC on 2023-06-21.
What is BNKL's market cap?
Bionik Laboratories Corp. (BNKL) has a market capitalization of $2.76M as of 2023-03-31.
What is BNKL's EPS (earnings per share)?
Bionik Laboratories Corp. (BNKL)'s trailing twelve month EPS is $-0.72 as of 2023-03-31.
What is BNKL's ROE (return on equity)?
Bionik Laboratories Corp. (BNKL)'s trailing twelve month Return on Equity (ROE) is -768.84% as of 2023-03-31.
What is BNKL's ROA (return on assets)?
Bionik Laboratories Corp. (BNKL)'s trailing twelve month Return on Assets (ROA) is -123.07% as of 2023-03-31.
What is BNKL's ROIC (return on invested capital)?
Bionik Laboratories Corp. (BNKL)'s trailing twelve month Return on Invested Capital (ROIC) is -889.21% as of 2023-03-31.
What is BNKL's EV/EBITDA?
Bionik Laboratories Corp. (BNKL)'s trailing twelve month EV/EBITDA is -0.94x as of 2023-03-31.